Oncology Pharma, Inc. engages in the development, manufacture and commercialization of therapeutics. The company is headquartered in San Francisco, California. The firm is focused on licensing, developing, manufacturing and commercializing therapeutics. The Company’s research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The firm offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Company’s NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.
ONPH'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
Oncology Pharma Inc'in en son EPS'si $ olup, $ beklentilerini .
Oncology Pharma Inc ONPH'ün son çeyrekteki geliri nasıl performans gösterdi?
Oncology Pharma Inc'in son çeyrek geliri $
Oncology Pharma Inc'in gelir tahmini nedir?
Wall Street analistine göre, Oncology Pharma Inc'in gelir tahmini $ ile $ arasında değişmektedir.
Oncology Pharma Inc'in kazanç kalite puanı nedir?
Oncology Pharma Inc'in kazanç kalite puanı B/34.51212'dir. Puan, karlılık, büyüme, nakit üretimi ve sermaye tahsisi ile kaldıraç olmak üzere dört boyuta dayanır.
Oncology Pharma Inc kazançlarını ne zaman rapor eder?
Oncology Pharma Inc'in bir sonraki kazanç raporu 'te bekleniyor